← Patent-cliff monitor small molecule IBRANCE PALBOCICLIB
Loss of exclusivity February 2037 latest FDA-listed patent expiry
Company Pfizer → See this company's full patent-cliff portfolio Drug detail Brand name IBRANCE Active ingredient PALBOCICLIB Strength 125MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval November 2019 Marketing status RX
Listed patents Patent Expires Type 11065250*PED February 2037 — 11065250 August 2036 product 10723730*PED August 2034 — 10723730 February 2034 substance, product RE47739*PED September 2027 — RE47739 March 2027 substance, product
Regulatory exclusivity Code Expires PED March 2029 M-14 September 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.